{
    "title": "Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles",
    "pmid": "28819312",
    "pmcid": "PMC5561238",
    "study_parameters": [
        {
            "Study Parameters ID": 1448926057,
            "Variant Annotation ID": 1448926055,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.32,
            "Confidence Interval Start": 1.42,
            "Confidence Interval Stop": 3.79,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926055"
        },
        {
            "Study Parameters ID": 1448926067,
            "Variant Annotation ID": 1448926065,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.32,
            "Confidence Interval Start": 1.42,
            "Confidence Interval Stop": 3.79,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926065"
        },
        {
            "Study Parameters ID": 1448925994,
            "Variant Annotation ID": 1448925992,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.32,
            "Confidence Interval Start": 1.42,
            "Confidence Interval Stop": 3.79,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448925992"
        },
        {
            "Study Parameters ID": 1448926047,
            "Variant Annotation ID": 1448926045,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.32,
            "Confidence Interval Start": 1.42,
            "Confidence Interval Stop": 3.79,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926045"
        },
        {
            "Study Parameters ID": 1448926111,
            "Variant Annotation ID": 1448926109,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.76,
            "Confidence Interval Start": 1.02,
            "Confidence Interval Stop": 3.02,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926109"
        },
        {
            "Study Parameters ID": 1448925915,
            "Variant Annotation ID": 1448925913,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.91,
            "Confidence Interval Start": 1.62,
            "Confidence Interval Stop": 5.23,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448925913"
        },
        {
            "Study Parameters ID": 1448926231,
            "Variant Annotation ID": 1448926229,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.18,
            "Confidence Interval Start": 0.07,
            "Confidence Interval Stop": 0.46,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926229"
        },
        {
            "Study Parameters ID": 1448925905,
            "Variant Annotation ID": 1448925903,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.91,
            "Confidence Interval Start": 1.62,
            "Confidence Interval Stop": 5.23,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448925903"
        },
        {
            "Study Parameters ID": 1448925984,
            "Variant Annotation ID": 1448925982,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.32,
            "Confidence Interval Start": 1.42,
            "Confidence Interval Stop": 3.79,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448925982"
        },
        {
            "Study Parameters ID": 1448926241,
            "Variant Annotation ID": 1448926239,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.18,
            "Confidence Interval Start": 0.07,
            "Confidence Interval Stop": 0.46,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926239"
        },
        {
            "Study Parameters ID": 1448926171,
            "Variant Annotation ID": 1448926169,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.18,
            "Confidence Interval Start": 0.07,
            "Confidence Interval Stop": 0.46,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926169"
        },
        {
            "Study Parameters ID": 1448926301,
            "Variant Annotation ID": 1448926299,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.0,
            "Confidence Interval Start": 1.23,
            "Confidence Interval Stop": 3.24,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926299"
        },
        {
            "Study Parameters ID": 1448925974,
            "Variant Annotation ID": 1448925972,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.32,
            "Confidence Interval Start": 1.42,
            "Confidence Interval Stop": 3.79,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448925972"
        },
        {
            "Study Parameters ID": 1448926101,
            "Variant Annotation ID": 1448926099,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.76,
            "Confidence Interval Start": 1.02,
            "Confidence Interval Stop": 3.02,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926099"
        },
        {
            "Study Parameters ID": 1448926091,
            "Variant Annotation ID": 1448926089,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.76,
            "Confidence Interval Start": 1.02,
            "Confidence Interval Stop": 3.02,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926089"
        },
        {
            "Study Parameters ID": 1448926291,
            "Variant Annotation ID": 1448926289,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.0,
            "Confidence Interval Start": 1.23,
            "Confidence Interval Stop": 3.24,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926289"
        },
        {
            "Study Parameters ID": 1448926037,
            "Variant Annotation ID": 1448926035,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.32,
            "Confidence Interval Start": 1.42,
            "Confidence Interval Stop": 3.79,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926035"
        },
        {
            "Study Parameters ID": 1448925960,
            "Variant Annotation ID": 1448925958,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.32,
            "Confidence Interval Start": 1.42,
            "Confidence Interval Stop": 3.79,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448925958"
        },
        {
            "Study Parameters ID": 1448926271,
            "Variant Annotation ID": 1448926269,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.0,
            "Confidence Interval Start": 1.23,
            "Confidence Interval Stop": 3.24,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926269"
        },
        {
            "Study Parameters ID": 1448926141,
            "Variant Annotation ID": 1448926139,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.76,
            "Confidence Interval Start": 1.02,
            "Confidence Interval Stop": 3.02,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926139"
        },
        {
            "Study Parameters ID": 1448926161,
            "Variant Annotation ID": 1448926159,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.18,
            "Confidence Interval Start": 0.07,
            "Confidence Interval Stop": 0.46,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926159"
        },
        {
            "Study Parameters ID": 1448926211,
            "Variant Annotation ID": 1448926209,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.18,
            "Confidence Interval Start": 0.07,
            "Confidence Interval Stop": 0.46,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926209"
        },
        {
            "Study Parameters ID": 1448998277,
            "Variant Annotation ID": 1448998275,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.32,
            "Confidence Interval Start": 1.42,
            "Confidence Interval Stop": 3.79,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448998275"
        },
        {
            "Study Parameters ID": 1448925885,
            "Variant Annotation ID": 1448925883,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.91,
            "Confidence Interval Start": 1.62,
            "Confidence Interval Stop": 5.23,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448925883"
        },
        {
            "Study Parameters ID": 1448926151,
            "Variant Annotation ID": 1448926149,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.76,
            "Confidence Interval Start": 1.02,
            "Confidence Interval Stop": 3.02,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926149"
        },
        {
            "Study Parameters ID": 1448925895,
            "Variant Annotation ID": 1448925893,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.91,
            "Confidence Interval Start": 1.62,
            "Confidence Interval Stop": 5.23,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448925893"
        },
        {
            "Study Parameters ID": 1448926024,
            "Variant Annotation ID": 1448926022,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.32,
            "Confidence Interval Start": 1.42,
            "Confidence Interval Stop": 3.79,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926022"
        },
        {
            "Study Parameters ID": 1448926281,
            "Variant Annotation ID": 1448926279,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.0,
            "Confidence Interval Start": 1.23,
            "Confidence Interval Stop": 3.24,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926279"
        },
        {
            "Study Parameters ID": 1448926014,
            "Variant Annotation ID": 1448926012,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.32,
            "Confidence Interval Start": 1.42,
            "Confidence Interval Stop": 3.79,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926012"
        },
        {
            "Study Parameters ID": 1448926077,
            "Variant Annotation ID": 1448926075,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.76,
            "Confidence Interval Start": 1.02,
            "Confidence Interval Stop": 3.02,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926075"
        },
        {
            "Study Parameters ID": 1448926201,
            "Variant Annotation ID": 1448926199,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.18,
            "Confidence Interval Start": 0.07,
            "Confidence Interval Stop": 0.46,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926199"
        },
        {
            "Study Parameters ID": 1448926131,
            "Variant Annotation ID": 1448926129,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.76,
            "Confidence Interval Start": 1.02,
            "Confidence Interval Stop": 3.02,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926129"
        },
        {
            "Study Parameters ID": 1448925875,
            "Variant Annotation ID": 1448925873,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.91,
            "Confidence Interval Start": 1.62,
            "Confidence Interval Stop": 5.23,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448925873"
        },
        {
            "Study Parameters ID": 1448926004,
            "Variant Annotation ID": 1448926002,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.32,
            "Confidence Interval Start": 1.42,
            "Confidence Interval Stop": 3.79,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926002"
        },
        {
            "Study Parameters ID": 1448926261,
            "Variant Annotation ID": 1448926259,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.0,
            "Confidence Interval Start": 1.23,
            "Confidence Interval Stop": 3.24,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926259"
        },
        {
            "Study Parameters ID": 1448926251,
            "Variant Annotation ID": 1448926249,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.18,
            "Confidence Interval Start": 0.07,
            "Confidence Interval Stop": 0.46,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926249"
        },
        {
            "Study Parameters ID": 1448926311,
            "Variant Annotation ID": 1448926309,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.0,
            "Confidence Interval Start": 1.23,
            "Confidence Interval Stop": 3.24,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926309"
        },
        {
            "Study Parameters ID": 1448925872,
            "Variant Annotation ID": 1448925862,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 1.0E-4",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 4.06,
            "Confidence Interval Start": 2.39,
            "Confidence Interval Stop": 6.88,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448925862"
        },
        {
            "Study Parameters ID": 1448926121,
            "Variant Annotation ID": 1448926119,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.76,
            "Confidence Interval Start": 1.02,
            "Confidence Interval Stop": 3.02,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926119"
        },
        {
            "Study Parameters ID": 1448925925,
            "Variant Annotation ID": 1448925923,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.91,
            "Confidence Interval Start": 1.62,
            "Confidence Interval Stop": 5.23,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448925923"
        },
        {
            "Study Parameters ID": 1448926181,
            "Variant Annotation ID": 1448926179,
            "Study Type": "case/control",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "NCT00310843)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.18,
            "Confidence Interval Start": 0.07,
            "Confidence Interval Stop": 0.46,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1448926179"
        },
        {
            "Study Parameters ID": 1449155766,
            "Variant Annotation ID": 1449155757,
            "Study Type": "case/control, clinical trial",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "Study Cohort: NCT00310843",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.07,
            "Confidence Interval Start": 1.12,
            "Confidence Interval Stop": 3.82,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": "1449155757"
        },
        {
            "Study Parameters ID": 1449155773,
            "Variant Annotation ID": 1449155771,
            "Study Type": "case/control, clinical trial",
            "Study Cases": 151.0,
            "Study Controls": 413.0,
            "Characteristics": "Study Cohort: NCT00310843",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.07,
            "Confidence Interval Start": 1.12,
            "Confidence Interval Stop": 3.82,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": "1449155771"
        }
    ],
    "var_drug_ann": [],
    "var_pheno_ann": [
        {
            "Variant Annotation ID": 1448926055,
            "Variant/Haplotypes": "HLA-B*67:01",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
            "Sentence": "HLA-B *67:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*67:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926055"
        },
        {
            "Variant Annotation ID": 1448926065,
            "Variant/Haplotypes": "HLA-B*78:01",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
            "Sentence": "HLA-B *78:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*78:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926065"
        },
        {
            "Variant Annotation ID": 1448925992,
            "Variant/Haplotypes": "HLA-B*51:02",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
            "Sentence": "HLA-B *51:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*51:02",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448925992"
        },
        {
            "Variant Annotation ID": 1448926045,
            "Variant/Haplotypes": "HLA-B*56:06",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
            "Sentence": "HLA-B *56:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*56:06",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926045"
        },
        {
            "Variant Annotation ID": 1448926109,
            "Variant/Haplotypes": "HLA-B*39:01",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
            "Sentence": "HLA-B *39:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*39:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926109"
        },
        {
            "Variant Annotation ID": 1448925913,
            "Variant/Haplotypes": "HLA-C*05:09",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
            "Sentence": "HLA-C *05:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*05:09",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448925913"
        },
        {
            "Variant Annotation ID": 1448926229,
            "Variant/Haplotypes": "HLA-B*15:32",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
            "Sentence": "HLA-B *15:32 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*15:32",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926229"
        },
        {
            "Variant Annotation ID": 1448925903,
            "Variant/Haplotypes": "HLA-C*05:01",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
            "Sentence": "HLA-C *05:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*05:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448925903"
        },
        {
            "Variant Annotation ID": 1448925982,
            "Variant/Haplotypes": "HLA-B*51:01",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
            "Sentence": "HLA-B *51:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*51:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448925982"
        },
        {
            "Variant Annotation ID": 1448926239,
            "Variant/Haplotypes": "HLA-B*15:35",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
            "Sentence": "HLA-B *15:35 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*15:35",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926239"
        },
        {
            "Variant Annotation ID": 1448926169,
            "Variant/Haplotypes": "HLA-B*15:12",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
            "Sentence": "HLA-B *15:12 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*15:12",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926169"
        },
        {
            "Variant Annotation ID": 1448926299,
            "Variant/Haplotypes": "HLA-DRB1*08:01",
            "Gene": "HLA-DRB1",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
            "Sentence": "HLA-DRB1 *08:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*08:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926299"
        },
        {
            "Variant Annotation ID": 1448925972,
            "Variant/Haplotypes": "HLA-B*39:10",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
            "Sentence": "HLA-B *39:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*39:10",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448925972"
        },
        {
            "Variant Annotation ID": 1448926099,
            "Variant/Haplotypes": "HLA-B*38:02",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
            "Sentence": "HLA-B *38:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*38:02",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926099"
        },
        {
            "Variant Annotation ID": 1448926089,
            "Variant/Haplotypes": "HLA-B*38:01",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
            "Sentence": "HLA-B *38:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*38:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926089"
        },
        {
            "Variant Annotation ID": 1448926289,
            "Variant/Haplotypes": "HLA-DRB1*04:04",
            "Gene": "HLA-DRB1",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
            "Sentence": "HLA-DRB1 *04:04 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*04:04",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926289"
        },
        {
            "Variant Annotation ID": 1448926035,
            "Variant/Haplotypes": "HLA-B*56:01",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
            "Sentence": "HLA-B *56:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*56:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926035"
        },
        {
            "Variant Annotation ID": 1448925958,
            "Variant/Haplotypes": "HLA-B*35:05",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-B*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
            "Sentence": "HLA-B *35:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*35:05",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448925958"
        },
        {
            "Variant Annotation ID": 1448926269,
            "Variant/Haplotypes": "HLA-DRB1*01:02",
            "Gene": "HLA-DRB1",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
            "Sentence": "HLA-DRB1 *01:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*01:02",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926269"
        },
        {
            "Variant Annotation ID": 1448926139,
            "Variant/Haplotypes": "HLA-B*39:09",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
            "Sentence": "HLA-B *39:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*39:09",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926139"
        },
        {
            "Variant Annotation ID": 1448926159,
            "Variant/Haplotypes": "HLA-B*15:01",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
            "Sentence": "HLA-B *15:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*15:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926159"
        },
        {
            "Variant Annotation ID": 1448926209,
            "Variant/Haplotypes": "HLA-B*15:27",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
            "Sentence": "HLA-B *15:27 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*15:27",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926209"
        },
        {
            "Variant Annotation ID": 1448998275,
            "Variant/Haplotypes": "HLA-B*35:10",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-B*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
            "Sentence": "HLA-B *35:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*35:10",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448998275"
        },
        {
            "Variant Annotation ID": 1448925883,
            "Variant/Haplotypes": "HLA-C*04:06",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
            "Sentence": "HLA-C *04:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*04:06",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448925883"
        },
        {
            "Variant Annotation ID": 1448926149,
            "Variant/Haplotypes": "HLA-B*57:01",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
            "Sentence": "HLA-B *57:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*57:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926149"
        },
        {
            "Variant Annotation ID": 1448925893,
            "Variant/Haplotypes": "HLA-C*04:07",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
            "Sentence": "HLA-C *04:07 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*04:07",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448925893"
        },
        {
            "Variant Annotation ID": 1448926022,
            "Variant/Haplotypes": "HLA-B*55:02",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
            "Sentence": "HLA-B *55:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*55:02",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926022"
        },
        {
            "Variant Annotation ID": 1448926279,
            "Variant/Haplotypes": "HLA-DRB1*01:03",
            "Gene": "HLA-DRB1",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
            "Sentence": "HLA-DRB1 *01:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*01:03",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926279"
        },
        {
            "Variant Annotation ID": 1448926012,
            "Variant/Haplotypes": "HLA-B*55:01",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
            "Sentence": "HLA-B *55:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*55:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926012"
        },
        {
            "Variant Annotation ID": 1448926075,
            "Variant/Haplotypes": "HLA-B*13:02",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
            "Sentence": "HLA-B *13:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*13:02",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926075"
        },
        {
            "Variant Annotation ID": 1448926199,
            "Variant/Haplotypes": "HLA-B*15:25",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
            "Sentence": "HLA-B *15:25 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*15:25",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926199"
        },
        {
            "Variant Annotation ID": 1448926129,
            "Variant/Haplotypes": "HLA-B*39:06",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
            "Sentence": "HLA-B *39:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*39:06",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926129"
        },
        {
            "Variant Annotation ID": 1448925873,
            "Variant/Haplotypes": "HLA-C*04:03",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
            "Sentence": "HLA-C *04:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*04:03",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448925873"
        },
        {
            "Variant Annotation ID": 1448926002,
            "Variant/Haplotypes": "HLA-B*54:01",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
            "Sentence": "HLA-B *54:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*54:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926002"
        },
        {
            "Variant Annotation ID": 1448926259,
            "Variant/Haplotypes": "HLA-DRB1*01:01",
            "Gene": "HLA-DRB1",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
            "Sentence": "HLA-DRB1 *01:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*01:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926259"
        },
        {
            "Variant Annotation ID": 1448926249,
            "Variant/Haplotypes": "HLA-B*52:01",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
            "Sentence": "HLA-B *52:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*52:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926249"
        },
        {
            "Variant Annotation ID": 1448926309,
            "Variant/Haplotypes": "HLA-DRB1*10:01",
            "Gene": "HLA-DRB1",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
            "Sentence": "HLA-DRB1 *10:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*10:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926309"
        },
        {
            "Variant Annotation ID": 1448925862,
            "Variant/Haplotypes": "HLA-C*04:01",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "In one allele logistic regression analyses HLA-C*04:01 was the only allele for which an association with cutaneous manifestations of nevirapine related hypersensitivity was observed across all ancestral groups.",
            "Sentence": "HLA-C *04:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*04:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448925862"
        },
        {
            "Variant Annotation ID": 1448926119,
            "Variant/Haplotypes": "HLA-B*39:05",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
            "Sentence": "HLA-B *39:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*39:05",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926119"
        },
        {
            "Variant Annotation ID": 1448925923,
            "Variant/Haplotypes": "HLA-C*18:01",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
            "Sentence": "HLA-C *18:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*18:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448925923"
        },
        {
            "Variant Annotation ID": 1448926179,
            "Variant/Haplotypes": "HLA-B*15:24",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
            "Sentence": "HLA-B *15:24 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*15:24",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1448926179"
        },
        {
            "Variant Annotation ID": 1449155757,
            "Variant/Haplotypes": "rs28399499",
            "Gene": "CYP2B6",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "The authors analyze rs28399499 T>C and rs3745274 G>A/T together as \"slow metabolizer\" genotypes.",
            "Sentence": "Allele C is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections as compared to allele T.",
            "Alleles": "C",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "T",
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1449155757"
        },
        {
            "Variant Annotation ID": 1449155771,
            "Variant/Haplotypes": "rs3745274",
            "Gene": "CYP2B6",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "Toxicity",
            "Significance": "not stated",
            "Notes": "The authors analyze rs28399499 T>C and rs3745274 G>A/T together as \"slow metabolizer\" genotypes.",
            "Sentence": "Allele T is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections as compared to allele G.",
            "Alleles": "T",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "G",
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1449155771"
        }
    ],
    "var_fa_ann": []
}